Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 16/20 | 0.77 |
| ▸ | ABL1 | P00519 | 2/20 | 0.77 |
| ▸ | BCR | P11274 | 1/20 | 0.77 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.63 |
| ▸ | EGFR | P00533 | 2/20 | 0.63 |
| ▸ | ABL2 | P42684 | 1/20 | 0.62 |
| ▸ | STK4 | Q13043 | 2/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5254809 | 0.89 | SRC (0.76) | SRCABL1BCRABL2STK4 | |
| SCHEMBL5198196 | 0.87 | SRC (1.00) | SRCABL1BCRERBB2EGFR | |
| SCHEMBL6181489 | 0.84 | SRC (0.84) | SRCABL1BCRERBB2EGFR | |
| SCHEMBL5253978 | 0.83 | SRC (0.75) | SRCABL1BCRABL2STK4 | |
| SCHEMBL5254963 | 0.82 | SRC (1.00) | SRCABL1BCRERBB2EGFR | |
| SCHEMBL22648371 | 0.82 | ERBB2 (0.75) | SRCABL1BCRERBB2EGFR | |
| SCHEMBL5261113 | 0.81 | STK4 (0.55) | SRCABL1BCRERBB2EGFR | |
| SCHEMBL6184168 | 0.80 | SRC (1.00) | SRCABL1BCRERBB2EGFR | |
| SCHEMBL6381771 | 0.80 | SRC (0.82) | SRCABL1BCRERBB2EGFR | |
| SCHEMBL5020080 | 0.80 | EGFR (0.78) | SRCERBB2EGFRSTK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1268487-B1 | TRICYCLIC PROTEIN KINASE INHIBITORS | WYETH CORP (US) | 2003-11-26 | — | — | EP | disclosed |
| US-6608048-B2 | Treatment of cancer, polycystic kidney disease and colonic polyps in mammals | WYETH HOLDINGS | 2003-08-19 | — | — | US | disclosed |
| US-20030065180-A1 | Tricyclic protein kinase inhibitors | AMERICAN HOME PRODUCTS CORPORATION (US) | 2003-04-03 | — | — | US | disclosed |
| EP-1268487-A1 | TRICYCLIC PROTEIN KINASE INHIBITORS | Wyeth (US) | 2003-01-02 | — | — | EP | disclosed |
| WO-2001072758-A1 | TRICYCLIC PROTEIN KINASE INHIBITORS | WYETH (US) | 2001-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030065180-A1 | Tricyclic protein kinase inhibitors | PKD1, PKD2, PKN1 | SRC 173/4885ABL1 179/4885BCR 2405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.